Resistance to the anti-cancer drug ilmofosine
Author Information
Author(s): J Hofmann, I Utz, M Spitaler, S Hofer, M Rybczynska, WT Beck, DBJ Herrmann, H Grunicke
Primary Institution: Institute of Medical Chemistry and Biochemistry, University of Innsbruck
Hypothesis
The study investigates the resistance of different cell lines to the anti-cancer drug ilmofosine.
Conclusion
Multidrug-resistant cells are cross-resistant to ilmofosine, and the compound does not interact directly with P-glycoprotein.
Supporting Evidence
- Multidrug-resistant cell lines showed cross-resistance to ilmofosine.
- Ilmofosine does not enhance the activity of doxorubicin or vinblastine.
- Dexniguldipine-HCl did not affect sensitivity to ilmofosine.
- Long-term treatment with ilmofosine did not induce multidrug resistance.
Takeaway
Some cancer cells can resist a new drug called ilmofosine, making it less effective. This happens because the cells have changes that help them avoid the drug's effects.
Methodology
The study involved testing various cell lines for their resistance to ilmofosine and analyzing the expression of multidrug resistance genes.
Limitations
The study does not provide a comprehensive understanding of all mechanisms of resistance to ilmofosine.
Want to read the original?
Access the complete publication on the publisher's website